Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VinEV-3 in Liver Cirrhosis
NCT07472270Phase 1Not yet recruiting
- Sponsor
- Vinmec Research Institute of Stem Cell and Gene Technology
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cell-derived extracellular vesicles in Liver cirrhosis (LC), sponsored by Vinmec Research Institute of Stem Cell and Gene Technology. Primary endpoint: Frequency and Severity of Adverse Events and Serious Adverse Events at 9 months. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
mesenchymal stem cell-derived extracellular vesicles
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT07472270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472270.